期刊文献+

高龄结直肠癌患者术后化疗依从性的影响因素分析 被引量:4

Factors Affecting Compliance of Postoperative Chemotherapy for Elderly Patients with Colorectal Cancer
下载PDF
导出
摘要 目的探讨高龄结直肠癌患者术后化疗的依从性及其影响因素。方法回顾性分析115例高龄结直肠癌患者的临床病例资料,其中65例接受术后辅助化疗,50例拒绝了术后化疗。对影响高龄结直肠癌患者术后化疗依从性的客观因素进行Logistic回归分析,并电话随访拒绝化疗患者的主观因素。结果多因素分析显示,性别、BMI、BSA、年龄及并发症是影响患者化疗依从性的独立因素(均P<0.05)。主观因素方面,有12例(60.0%)Ⅱ期结直肠癌患者拒绝化疗是因为医生的建议程度不够。患者的恐惧心理(20.0%,3/15)、经济条件(20.0%,3/15)及对预后的绝望情绪(27.3%,3/11)是影响Ⅲ、Ⅳ期患者接受化疗的主要原因。结论患者的性别、BMI、BSA、年龄、并发症是影响高龄结直肠癌术后化疗依从性的客观指标。对于Ⅱ期患者,医生对化疗的建议程度应该加强;对于Ⅲ期患者,应调节患者负性情绪。 Objective To investigate the compliance of postoperative chemotherapy for elderly patients with colorectal cancer and influence factors. Methods Clinicopathological data of 115 elderly patients( 〉70 years old) with stage II - IV colorectal cancer were retrospectively reviewed. 65 cases received postoperative chemotherapy and 50 refused. Logistic regression mod- el was used to analyze factors affecting compliance of postoperative chemotherapy. Patients were followed up by phone call regarding the reason for refusal. Results Multivariate analysis showed that gender, body mass index( BMI), body surface area( BSA), age and complication were independent risk factors associated with chemotherapy compliance ( All P 〈 0.05 ). Follow-up phone questionnaire showed that 12(60.0% )patients with stage II colorectal cancer did not receive chemotherapy because the doctor did not offer sufficient advice. For stage III, IV patients, fear of chemotherapy( 20.0% ,3/15 ), financial issues (20.0%, 3/15 ) and desperate feelings about prognosis(27.3% ,3/11 ) were the main factors affecting patients' receiving chemotherapy. Conclusions Gender, BMI, BSA, age and complications are the main factors associated with compliance of postoperative chemotherapy. Doctors" recommendation should be emphasized for stage II patients. For stage III patients, patients" negative emotions should be adjusted.
作者 姚勤红
出处 《实用癌症杂志》 2013年第6期689-692,共4页 The Practical Journal of Cancer
关键词 结直肠癌 高龄 术后化疗 影响因素 Colorectal neoplasms Elderly Postoperative chemotherapy Influence factor
  • 相关文献

参考文献11

  • 1Baldueci L, Cohen HJ, Engstrom PF, et al. Senior aduh on- cology clinical practice guidelines in oncology [ J ]. J Natl Compr Cane Netw,2005,3 (4) : 572.
  • 2Biagi J J, Raphael M J, Maekillop WJ, et al. Association be- tween time to initiation of adjuvant chemotherapy and surviv- al in colorectal cancer: a systematic review and meta-analy- sis[ J ]. JAMA,2011,305 (22) :2335.
  • 3Bijelie L, Yan TD, Sugarbaker PH. Treatment failure follow- ing complete cytoreduetive surgery and perioperative intrap- eritoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms [ J ]. J Surg Onco1,2008,98 ( 4 ) :295.
  • 4Consolo P, Luigiano C, Pellicano R, et al. Endoscopic resec- tion as a safe and effective technique for treatment of pedun-culated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size [ J]- Minerva Med,2010,101 (5) :311.
  • 5Kahenbach T, Soetikno R. Image-enhanced endoscopy is cr- itical in the detection, diagnosis, and treatment of non-poly- poid colorectal neoplasms [ J]. Gastrointest Endosc Clin N Am,2010,20(3) :471.
  • 6蒋蔚茹,刘杰.结直肠癌化疗进展[J].中国肿瘤,2011,20(3):200-203. 被引量:25
  • 7Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled anal- ysis of safety and efficacy of oxaliplatin plus fluorouracil/ leucovorin administered bimonthly in elderly patients with colorectal cancer[ J ]. J Clin Oncol,2006,24(25):4085.
  • 8Cheung WY, Neville BA, Earle CC. Etiology of delays in the initiation of adjuvant chemotherapy and their impact on out- comes for Stage 11 and HI rectal cancer[J ]. Dis Colon Rec- tum,2009,52(6) : 1054.
  • 9王建彬,杨宇飞.结直肠癌术后中医药治疗的多中心前瞻性队列研究的监查[J].医学研究杂志,2011,40(10):17-19. 被引量:4
  • 10丁义江,吴崑岚.中医在结直肠癌综合治疗中的作用[J].中华消化外科杂志,2010,9(6):405-407. 被引量:2

二级参考文献51

  • 1张思维,雷正龙,李光琳,邹小农,陈万青,赵平.中国肿瘤登记地区2005年发病死亡资料分析[J].中国肿瘤,2009,18(12):973-979. 被引量:32
  • 2王文,马丽媛,邹效漫.国际多中心临床试验的监查[J].中国临床药理学与治疗学,2004,9(7):835-837. 被引量:9
  • 3王越华,李兆元,龚先奇.康莱特注射液联合化疗治疗晚期结直肠癌[J].肿瘤,2006,26(12):1137-1138. 被引量:14
  • 4商洪才,张俊华,戴国华,曹红波,任明,项耀祖,汪洋,张伯礼,李幼平.中药大规模临床试验及其管理与质量控制[J].中西医结合学报,2007,5(1):1-4. 被引量:21
  • 5Goldberg RM,Meropol NJ,Tabemero J, et al. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer [J]. Castrointest Cancer Res, 2009, 3(Suppl 2):S23-S27.
  • 6Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001 [J]. CA Cancer J Clin, 2001,51(1):15-36.
  • 7Andra T, Boni C, Mounedji-Boudiaf L, et al. Multieenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J]. N Engl J Med, 2004, 350(23):2343-2351.
  • 8Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma [J]. N Engl J Med, 1990, 322 (6): 352-358.
  • 9Falcone A, Masi G, Brunetti I, et al. The triplet combination of irinoteean, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOI,FIRI) as first-line treatment of metastatic colorectal cancer (MCRC): resuits of a randomized phase III trial by the Gruppo Oncologico Nord Ovest(G.O. N.O.)[J]. J Clin Oncol, 2006, 24:18S.
  • 10Andra T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial [J]. J Clin Oncol, 2009, 27(19): 3109-3116.

共引文献33

同被引文献34

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部